Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response.

Shcherbakov DN, Bakulina AY, Karpenko LI, Ilyichev AA.

Acta Naturae. 2015 Oct-Dec;7(4):11-21.

2.

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J.

J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15.

PMID:
26763999
3.

Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.

Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K, Zhang R, Sutherland LL, Scearce RM, Bowman CM, Stolarchuk C, Lloyd KE, Parks R, Eaton A, Foulger A, Nie X, Karim SS, Barnett S, Kelsoe G, Kepler TB, Alam SM, Montefiori DC, Moody MA, Liao HX, Morris L, Santra S, Harrison SC, Haynes BF.

Cell Rep. 2016 Jan 5;14(1):43-54. doi: 10.1016/j.celrep.2015.12.017. Epub 2015 Dec 24.

4.

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S.

J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.

5.

The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection.

Cortez V, Wang B, Dingens A, Chen MM, Ronen K, Georgiev IS, McClelland RS, Overbaugh J.

PLoS Pathog. 2015 Jul 9;11(7):e1004973. doi: 10.1371/journal.ppat.1004973. eCollection 2015 Jul.

6.

Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.

Khan L, Makhdoomi MA, Kumar S, Nair A, Andrabi R, Clark BE, Auyeung K, Bhattacharya J, Vajpayee M, Wig N, Pantophlet R, Luthra K.

PLoS One. 2015 May 11;10(5):e0125575. doi: 10.1371/journal.pone.0125575. eCollection 2015.

7.

A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Dunkel A, Shen S, LaBranche CC, Montefiori D, McGettigan JP.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1126-38. doi: 10.1089/AID.2014.0319. Epub 2015 May 5.

PMID:
25848984
8.

Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.

J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11.

9.

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Moore PL, Williamson C, Morris L.

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5. Review.

10.

An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virus.

Bęczkowski PM, Logan N, McMonagle E, Litster A, Willett BJ, Hosie MJ.

J Gen Virol. 2015 Mar;96(Pt 3):671-80. doi: 10.1099/vir.0.071522-0. Epub 2014 Nov 13.

11.

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.

Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M.

Nature. 2014 Nov 6;515(7525):138-42. doi: 10.1038/nature13601. Epub 2014 Sep 3.

12.

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.

Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, Stamatatos L.

J Virol. 2014 Nov;88(22):12968-81. doi: 10.1128/JVI.01816-14. Epub 2014 Aug 13.

13.

The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.

Manhas S, Chau D, Rempel C, Clark BE, Auyeung K, Pantophlet R.

Virology. 2014 Aug;462-463:98-106. doi: 10.1016/j.virol.2014.05.034. Epub 2014 Jun 25.

14.

Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies.

Kelsoe G, Verkoczy L, Haynes BF.

Vaccines (Basel). 2014 Mar;2(1):1-14. doi: 10.3390/vaccines2010001.

15.

An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.

Bonsignori M, Wiehe K, Grimm SK, Lynch R, Yang G, Kozink DM, Perrin F, Cooper AJ, Hwang KK, Chen X, Liu M, McKee K, Parks RJ, Eudailey J, Wang M, Clowse M, Criscione-Schreiber LG, Moody MA, Ackerman ME, Boyd SD, Gao F, Kelsoe G, Verkoczy L, Tomaras GD, Liao HX, Kepler TB, Montefiori DC, Mascola JR, Haynes BF.

J Clin Invest. 2014 Apr;124(4):1835-43. doi: 10.1172/JCI73441. Epub 2014 Mar 10.

16.

The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties.

Lorenz IC, Nguyen HT, Kemelman M, Lindsay RW, Yuan M, Wright KJ, Arendt H, Back JW, DeStefano J, Hoffenberg S, Morrow G, Jurgens CK, Phogat SK, Zamb TJ, Parks CL.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1130-44. doi: 10.1089/AID.2013.0206. Epub 2014 Apr 9.

17.

Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.

Carbonetti S, Oliver BG, Glenn J, Stamatatos L, Sather DN.

PLoS One. 2014 Jan 23;9(1):e86905. doi: 10.1371/journal.pone.0086905. eCollection 2014.

18.

Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Bissett SL, Draper E, Myers RE, Godi A, Beddows S.

Vaccine. 2014 Feb 26;32(10):1139-46. doi: 10.1016/j.vaccine.2014.01.008. Epub 2014 Jan 15.

19.

Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.

Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD.

J Virol. 2014 Mar;88(5):2426-41. doi: 10.1128/JVI.02837-13. Epub 2013 Dec 11.

20.

Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.

McLinden RJ, Labranche CC, Chenine AL, Polonis VR, Eller MA, Wieczorek L, Ochsenbauer C, Kappes JC, Perfetto S, Montefiori DC, Michael NL, Kim JH.

PLoS One. 2013 Nov 28;8(11):e77756. doi: 10.1371/journal.pone.0077756. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk